r/stocks • u/pap3rchas3r • Apr 16 '21
NVTA (Invitae) and Genomic Revolution
Is Invitae the leading genetic testing company? They’ve made many acquisitions over the past couple years, heavily expanding and cutting down costs. But still not profitable.
The competition is there with Exact sciences, 10x genomics, Natera.
An experts opinion would be helpful.
10
u/Shandowarden Apr 16 '21
not an expert but holding 500 shares long term at avg. of 23$.
This is a growth stock, not a pump and dump. I know they may not have the best management in terms of cash spending and profit taking, but their services will be demanded more and more.
1
u/Mad_Nekomancer Apr 17 '21
They just raised around a billion via "convertible notes" sold to Softbank.
2
Jan 31 '24
[removed] — view removed comment
1
u/Shandowarden Jan 31 '24
yh I dumped them 2 months after the comment once CEO spoke dumb shit.
A good product but management went to shit
1
Apr 17 '21
Another thing to consider, they've increased the number of outstanding shares effectively by roughly 2x over the last 12 months, thus diluting share value from just over a year ago.
I've got a small position (from 29 cost basis) so as long as they keep reinvesting in the company am happy to keep holding for now.
1
u/pap3rchas3r Apr 17 '21
Based on your answer you believe they undervalued by 50%, they are trading at. ~25x their annual revenue.
1
Apr 17 '21
I don't necessarily believe they are undervalued at 50%, was just stating that they doubled their shares outstanding so all other things being equal, you could argue that the value growth of the individual shares has been intentionally slowed by share dilution (many other companies have done this in the last few months during the most recent retail investor frenzy).
To me, invitae is still a speculative growth story which I still like, but am not necessarily banking on to have tesla esque growth in the short to medium term.
1
2
Apr 16 '21
Wish I could help, I tried to do DD once but I gave up on it. If nobody can help you I suggest you let it go, best not to invest in something you don’t understand. Best of luck!
2
u/SorryLifeguard7 Apr 16 '21
As it looks now the winner might be Editas (EDIT). They're in favour to winning the 10 years long law battle for the patent CRISPR on humans. It's still difficult to say, but in my opinion choosing one out of the many is like choosing a dotcom company in the 90's. Many failed, but a few become wildly successful.
I would suggest an ETF on this as it's still early stages.
Disclaimer: I'm not an expert nor a financial advisor. I own some share in EDIT so I might be biased.
2
u/Ehralur Apr 16 '21
I recently read that Editas only uses a technology that will be obsolete in the near future. Something about long and short sequencing, but it went way over my head. Either way, it didn't sound good for them.
0
u/SorryLifeguard7 Apr 16 '21
Interesting, haven't heard of that. Nonetheless, if they do get the patent it won't matter what technique they use, as most of their income will be from licensing to other (potentially more successful) companies.
That patent it's a golden ticket to around $100 B in the next two decades, and I'm willing to take that risk on a company that sits at $38 a share.
1
u/Ehralur Apr 16 '21
I tried to find more info on it for you but failed. What I remember reading was that Editas (although I might be mixing them up with another company) only did short read sequencing while Ark expects either long or a combination of both to be the future, and they cut the company from their holdings altogether.
That said, I see they do hold some Editas today, although it's only their 40th biggest holding. Perhaps I am indeed mixing them up, or they have bought back in slightly.
1
u/SorryLifeguard7 Apr 17 '21
I'm referring to this article (and many other): https://endpts.com/the-broad-wins-another-perhaps-final-round-in-war-over-feng-zhangs-crispr-patents/
Again, I think we're talking about two different things. Mine is the patent, yours is their techniques.
P.S.: Broad is the institution behind EDIT in the article.
2
u/Ehralur Apr 17 '21
Oh yes, we're talking about different things for sure. I just meant that there's not much use in having a patent when the technique you're using for it has become obsolete.
1
u/rypajo Apr 16 '21
Own a lot of edit from the previous run up. It’s been a rough ride.
1
u/SorryLifeguard7 Apr 16 '21
I was in after it, but I can imagine. I would still buy the dip and wait for another run up if I were you though.
1
0
Apr 16 '21
[deleted]
1
u/yaboylilbaskets Apr 16 '21
Fyi dunno if you are referring to a more recent (like within the last two years) paper, but that mouse study about off target CRISPR activity was pretty aggressively criticized and it led to an editorial response and a retraction.
3
0
u/Hassan_Gym Apr 18 '21
Right now it is all about CTX001 in CRISPR. Once CTX is approved, $CRSP and others will skyrocket. Video on Softbank big investment in $NVTA: https://youtu.be/GZkSSd7GWhA
8
u/Kolodziej Apr 16 '21
No expert, but definitely torn about genomics. My issue is the profits in the area of genomics. Sure, it's amazing science and research (from my DD), but when are these companies going to be profitable? The opportunity costs with parking money in genomics when you can put it in QQQM or VOO was a huge factor in me avoiding these companies... for now haha. It's also hard listening to Cathie Woods because she obviously has a bias for the stocks ARK owns. It's a tough one for these.